These results imply the following: loss of CDK2-AP1 activates CDK2 and CyclinD1 continuously, which in turn increases the ratio of bcl2/bax probably by upregulating bcl2, which finally enhances resistance to apoptosis in the cancer cells. This evidence concerns the gene CCND1 and cancer.